A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease.
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2010
At a glance
- Drugs Sibutramine (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 May 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 29 Nov 2007 Results reported in an Eisai media release.